• A friendly and supportive community, register today. Our forums use a separate account system.

Clinics CB1 Medical

As you suggested, free for personnel of various national services or armed forces veterans - otherwise £50 per year. By far the cheapest clinic, with generally favourable reviews as far as we've seen.

You can use any pharmacy at CB1 Medical, though they also have a public formulary for their own pharmacy posted here:

 
As you suggested, free for personnel of various national services or armed forces veterans - otherwise £50 per year. By far the cheapest clinic, with generally favourable reviews as far as we've seen.

You can use any pharmacy at CB1 Medical, though they also have a public formulary for their own pharmacy posted here:

Cheers, I get it now, I was thinking it was £50 for personnel of various national services and armed forces veterans and couldn't find prices for others, making me think it was exclusive. Going to look into this , the cost over a year for a new patient not just the £50 but the oils and flower costs with any Grow Access Project or T21 discount if applicable for someone, must admit looks promising compared to some others at first glance.
 
The idea of less frequent appointments matters. Makes CB1 Medical attractive, if also true like Mamedica®.
Great feeling having no consultation required for bout another nine months for me, difference is this person would probably need guidance with the oils and I'd imagine the need for THC/high CBD oil so may need more consultations as they find out what works for them oilwise, so would not like the outlay for an access scheme that becomes value in the second year encase the benefits of MC are not significant enough also these oils I suspect they would need tend to be really dear. With me the need for guidance isn't as essential as I've treated my mental health and kept it check myself with cannabis for years.I just needed access to the tools so to speak.
 
To be fair to them, I worry slightly about their business model, if too many prescriptions are fulfilled external to their formulary.

When clinic costs are low, squaring the circle of a sustainable business is possible when it's all dispensed in house. When it's dispensed externally instead, they don't get that revenue cut. So their business is less lubricated.

They likely can't charge for external prescriptions only because they are external, for basic regulatory reasons. Independence / freedom of prescribing and dispensing maintains patient choice). So they can't go that way.... In pure commercial law terms, it would also be an anticompetitive restrictive trading practice.

Maybe the sums can be made to add up - I don't have their books. But I do worry about whether these fast growing young businesses stay liquid. It's a classic that businesses make enough revenue on paper, but cashflows crunch. Let alone recruitment challenges or just making enough revenue full stop.

@Muiredach, if my superficial worry is real. A central product DB like MedBud and its inventory data per SKU could be a solution for industry stability. An industry utility. Compatible with the current vision. And not locked into commercial operations, which others' equivalent solutions would be.

If stock data is up to date, then just on time wholesaling and drop shipping is made easier for pharmacies. Which would matter, cos it would avoid any need for dubious external-only prescription charges. Instead, pharmacies could instead confidently list xyz that they don't actually stock, but with a little markup that compensates for lost revenue when it's fulfilled by another pharmacy.

Some people might wonder what I'm on about... But CB1 Medical offers super lean pricing, and the clinics have to be durable. The same would also facilitate lower pricing outfits, who aren't subsidising clinic consultation for their patients.

If they aren't durable, we'll go in a spiral of Jorja Emerson Centre type problems or worse. And if that keeps happening, there will be serious and negative policy attention by government or regulators. Which might be a negatively prejudicial.
 
Last edited:
To be fair to them, I worry slightly about their business model, if too many prescriptions are fulfilled external to their formulary.

When clinic costs are low, squaring the circle of a sustainable business is possible when it's all dispensed in house. When it's dispensed externally instead, they don't get that revenue cut. So their business is less lubricated.
This is something that did occur to us and the hope is that prescriptions can be satisfied inhouse without too much of a compromise ,as I feel when signing up in this instance your sort of buying into their way . Also like the way it seems more closely aligned to the NHS , I may be wrong ,but the feedback to the NHS I would of thought that only good would come of this eventually.
 
The NHS side of it makes applying easier, but is less about alignment, and more about API/geek access to commercial medical record systems like EMIS.

That's how commercial apps for patients get access. Apps like the Patient Access and even the eventual English NHS app that did come along.

(But my understanding is that's all API access, cached temporarily, not stored. Hence the Palantir discussions in the media, which will not just be about signing the contract, but also to allow storage/copying to facilitate analytics. Personally, I'd trust that Palantir as far as I could throw Omnicorp from RoboCop, with lots of inside reasons for saying that).
 
Just installed the app. Tried filling everything out it said it is missing but it's gonna take a lot of getting used too for me personally. The request system was so simple before.

trying to put my request in and it is giving me a THC limit reached when trying to add to the request more than one item above 20% THC and I'm well within this months prescriptions allowance.

I really hope I have just done something wrong or there's just a few glitches in the system they can fix soon. I cant wrap my head around it at the moment. Caught myself a lovely cough few days ago so my brain is too fuzzy to focus on dealing with the app at the moment.
 
Just installed the app. Tried filling everything out it said it is missing but it's gonna take a lot of getting used too for me personally. The request system was so simple before.

trying to put my request in and it is giving me a THC limit reached when trying to add to the request more than one item above 20% THC and I'm well within this months prescriptions allowance.

I really hope I have just done something wrong or there's just a few glitches in the system they can fix soon. I cant wrap my head around it at the moment. Caught myself a lovely cough few days ago so my brain is too fuzzy to focus on dealing with the app at the moment.

Seems they have only just adopted Script Assist and its app literally yesterday. Teething problems will be natural and to be expected. I had a few, which they sorted. Simple enough to use to be honest, but no other progress yet to me. Will be patient for now... I had no app or menu before, so it looks like an upgrade for me. Let's see.

View attachment 448View attachment 447
More good news thanks to MedBud and CB1 Medical for looking to improve patients choices.

I do hope that this will be a real process with follow through. Access to flower they don't have yet can be critical, and getting access is a key way for them to retain business and stay financially healthy. It's not just about getting GLO products.

@Muiredach did you get any feeling from them they understand that flower choice is not just about THC/CBD levels and that different product's curing and strains can lead to different terpene profiles? Otherwise, there's a risk that actual follow through could be slow or not really happen.
 
From what I understand this is indeed a teething issue/bug, and should ultimately be resolved. I've otherwise heard recently that Script Assist report no major issues so far with launch and that they're quickly patching minor bugs.

(We're expecting Integro's app to launch before too long too, and it can already be installed.)

@Muiredach did you get any feeling from them they understand that flower choice is not just about THC/CBD levels and that different product's curing and strains can lead to different terpene profiles? Otherwise, there's a risk that actual follow through could be slow or not really happen.
This is overall a hard argument to make, clinicians are foremost receptive to considering quantifiable metrics. If they can see something on a COA or in other official info provided which could impact suitability they'll consider it, but to them things like the difference between curing/cultivars is not really tangible in their self-verifiable data as provided to them by authoritative sources.

In short clinicians don't have much to go on beyond THC/CBD, and in some cases terpene information and irradiation method. For the latter, it's hard to even know how to interpret values based on authoritative peer-reviewed research, studies, data et cetera.
 
Access to flower they don't have yet can be critical, and getting access is a key way for them to retain business and stay financially healthy.

This is the thing for any dispensing business to understand. Because market forces will dominate. And CB1 Medical people seem smart (I've just been overthinking since Jorja Emerson Centre).

If there is a reasonable hypothesis of a strain upside (there is already broad terpene research that is sufficiently generalisable) and with no likely clinical downside or material difference in cost, a medic should have zero problem.

That's a reasonable way of thinking for any choice of clinician for anything - to filter our cookie cutter medicine. Not always simple, even in private healthcare and esp in NHS contexts, but doable.

That does of course depend on an easy registry of complete information. Which of course is entirely the point of Medbud from a medic's perspective.

This is overall a hard argument to make, clinicians are foremost receptive to considering quantifiable metrics. If they can see something on a COA or in other official info provided which could impact suitability they'll consider it, but to them things like the difference between curing/cultivars is not really tangible in their self-verifiable data as provided to them by authoritative sources.

In short clinicians don't have much to go on beyond THC/CBD, and in some cases terpene information and irradiation method. For the latter, it's hard to even know how to interpret values based on authoritative peer-reviewed research, studies, data et cetera.
I totally get that this will be the instinct of many clinicians. Quantifiable science is a positive counterweight to quackery.

Flip side is the cost of misplaced risk-aversion, often by avoiding absolutely anything that is unquantified. It's also a problem outside of MC. This often means too many medics are comfortable with inferior/horrific outcomes, if they can be justified by an irrelevant application of quants. Especially when medics grasp for numerical comfort blankets to manage their fears of scrutiny. It's cultural mindset problem common in many professions. Of course, usually not knowingly. Sometimes it's down to lack of time or underconfidence. Sometimes it's just poor scientific instincts.

Best practice recognises that medical practice is the artful application of science in xyz context. And those docs realise that medical practice is not a science in itself. Confident/experienced/passionate medics realise that 1) specific numbers only measure X, 2) do not measure Y and that 3) accounting for Z can more than just compatible with the known numbers, but be clinically necessary or effectively riskless.
 
Last edited:
also a problem outside of MC.
One of many examples:

 
Back
Top